http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Amaylia Oehadian ),( Emmy Pranggono ),( Uun Sumardi ),( Hadi Jusuf ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Monocytes could be infected with infi uenza virus and induce rapid differentiation into myeloid dendritic cells (mDCs). Virus-induced mDCs secreted chemoattractants for monocytes (MCP-1 and IP-10). We aim to evaluate monocyte, chemoattractans for monocytes and IFNalpha in infi uenza virus H5N1 and H1 N1. Secondary data were evaluated from medical record of H5N1(n=10) and H1N1 ( n=8) who were hospitalized in Hasan Sadikin Hospital since 2005. MCP-1, IP-10 and IFNalpha were evaluated using secondary data from previous study by Jusuf H : A Comparison of cytokine level between infi uenza A (H5N1) with infi uenza A (pH1N1) Mann Whitney test was used for comparison between H5N1 and H1N1, survive and death subjects. The correlation between chemoattractans for monocytes (MCP-1 and IP-10), IFNalpha and monocyte count were calculated using Spearmann correlation test. Monocyte count was lower in H5N1 compare to H1N1 (90 (0-240) vs 139 (36-560)/mm3, p 0. 17). Monocyte count was higher in survive compare to death subjects (150 (0-560) vs 75 (36-240) /mm3, p 0. 09). The death subjects had signifi cantly higher MCP-1, IP10 and IFNaplha (2171. 5 (985- 10000) vs 674. 4 (450. 2-1209. 3) pg/ml, p 0. 03, 3186. 9 (2436, 2-3937. 6) vs 971. 4 (520, 7-2387. 4) pg/ml, p 0. 03 and 354. 0 (87-2499. 8) vs 18, 6 (1. 41-184) pg/ml, p 0. 003, respectively). There was strong and signifi cant negative correlation between monocytes count and MCP-1 ( R -0. 8, p 0. 042) and between monocytes count andIP-10 ( R -0. 8, p 0. 019). Monocyte count could be used to characterized the severity of infi uenza viral infection. The lower monocyte count correlate with the higher chemoattractant for monocytes produced by mDCs.
( Amaylia Oehadian ),( Prayudi Santoso ),( Dick Menzies ),( Rovina Ruslami ) 대한결핵 및 호흡기학회 2022 Tuberculosis and Respiratory Diseases Vol.85 No.2
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.
Rovina Ruslami,Amaylia Oehadian,Prayudi Santoso,Dick Menzies 대한결핵및호흡기학회 2022 Tuberculosis and Respiratory Diseases Vol.85 No.2
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.